当前位置: X-MOL 学术Epilepsy Curr. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
CRAFTing a New Approach to Antiepileptic Drug Discovery.
Epilepsy Currents ( IF 5.8 ) Pub Date : 2019-05-01 , DOI: 10.1177/1535759719842148
Kyle A. Lyman , Dane M. Chetkovich

Srivastava PK, van Eyll J, Godard P, Mazzuferi M, Delahaye-Duriez A, Steenwinckel JV, et al. A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target. Nat Commun. 2018;9(1):3561. doi:10.1038/s41467-018-06008-4. The identification of drug targets is highly challenging, particularly for diseases of the brain. To address this problem, we developed and experimentally validated a general computational framework for drug target discovery that combines gene regulatory information with causal reasoning ("Causal Reasoning Analytical Framework for Target discovery"-CRAFT). Using a systems genetics approach and starting from gene expression data from the target tissue, CRAFT provides a predictive framework for identifying cell membrane receptors with a direction-specified influence over disease-related gene expression profiles. As proof of concept, we applied CRAFT to epilepsy and predicted the tyrosine kinase receptor Csf1R as a potential therapeutic target. The predicted effect of Csf1R blockade in attenuating epilepsy seizures was validated in 3 preclinical models of epilepsy. These results highlight CRAFT as a systems-level framework for target discovery and suggest Csf1R blockade as a novel therapeutic strategy in epilepsy. The CRAFT is applicable to disease settings other than epilepsy.

中文翻译:

研究抗癫痫药物发现的新方法。

Srivastava PK,van Eyll J,Godard P,Mazzuferi M,Delahaye-Duriez A,Steenwinckel JV等。用于药物发现的系统级框架将Csf1R识别为抗癫痫药的目标。Nat Commun。2018; 9(1):3561。doi:10.1038 / s41467-018-06008-4。药物靶标的鉴定非常具有挑战性,特别是对于脑部疾病。为了解决这个问题,我们开发并实验验证了用于药物靶标发现的通用计算框架,该框架将基因调控信息与因果推理相结合(“目标发现的因果推理分析框架” -CRAFT)。使用系统遗传学方法并从目标组织的基因表达数据开始,CRAFT提供了一个预测框架,用于识别对疾病相关基因表达谱具有方向特定影响的细胞膜受体。作为概念的证明,我们将CRAFT应用于癫痫病并预测酪氨酸激酶受体Csf1R是潜在的治疗靶点。在3种临床前癫痫模型中验证了Csf1R阻断在减轻癫痫发作中的预期作用。这些结果突出了CRAFT作为靶标发现的系统级框架,并建议Csf1R阻断是癫痫的一种新型治疗策略。CRAFT适用于癫痫以外的疾病。在3种临床前癫痫模型中验证了Csf1R阻断在减轻癫痫发作中的预期作用。这些结果突出了CRAFT作为靶标发现的系统级框架,并建议Csf1R阻断是癫痫的一种新型治疗策略。CRAFT适用于癫痫以外的疾病。在3种临床前癫痫模型中验证了Csf1R阻断在减轻癫痫发作中的预期作用。这些结果突出了CRAFT作为靶标发现的系统级框架,并建议Csf1R阻断是癫痫的一种新型治疗策略。CRAFT适用于癫痫以外的疾病。
更新日期:2019-04-29
down
wechat
bug